Short answer
PepGen Inc (PEPG) filed its Q3 2026 10-Q quarterly report on Nov 10, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$19M
- −7.6% YoY · −8.9% QoQ
- EPS (diluted)
- −$0.28
- +45.1% YoY · −12.0% QoQ
Source: XBRL data from the PepGen Inc (PEPG) Q3 2026 10-Q on SEC EDGAR. USD.
PepGen Inc Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no product sales since inception
- Net loss $19.4M vs $18.0M YoY, operating loss $20.4M vs $18.7M
- R&D expense $14.5M vs $13.4M, PGN-EDODM1 external expense $7.7M vs $5.4M
- Cash, equivalents and marketable securities $104.8M at September 30, 2026, funding planned operations into 2028
- Operating cash use $47.4M for nine months, ATM proceeds $1.5M, FREEDOM2 remains on partial U.S. clinical hold
Risk Factors
- Newly added BIOSECURE Act risk: WuXi AppTec’s June 2026 Section 1260H designation could trigger OMB BCC designation and supplier transition costs
- Regulatory risk: FDA partial clinical hold announced March 2026 requires additional nonclinical mouse studies for FREEDOM2
- Operational risk: Single-source API and finished-product suppliers could disrupt PGN-EDODM1 clinical development
- Financial risk: $104.8 million cash, equivalents and marketable securities as of September 30, 2026, with additional funding needed beyond 2026 readouts
- Market risk: PGN-EDODM1 remains PepGen’s only active clinical program after PGN-EDO51 discontinuation in May 2025
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.